Rascol O - Search Results

1

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. Palfi S, et al. Among authors: rascol o. Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10. Lancet. 2014. PMID: 24412048 Clinical Trial.

2

Treatment interventions for Parkinson's disease: an evidence based assessment.

Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Rascol O, et al. Lancet. 2002 May 4;359(9317):1589-98. doi: 10.1016/S0140-6736(02)08520-3. Lancet. 2002. PMID: 12047983 Review.

3

Limitations of current Parkinson's disease therapy.

Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Rascol O, et al. Ann Neurol. 2003;53 Suppl 3:S3-12; discussion S12-5. doi: 10.1002/ana.10513. Ann Neurol. 2003. PMID: 12666094 Review.

4

Subthalamic nucleus stimulation reduces abnormal motor cortical overactivity in Parkinson disease.

Payoux P, Remy P, Damier P, Miloudi M, Loubinoux I, Pidoux B, Gaura V, Rascol O, Samson Y, Agid Y. Payoux P, et al. Among authors: rascol o. Arch Neurol. 2004 Aug;61(8):1307-13. doi: 10.1001/archneur.61.8.1307. Arch Neurol. 2004. PMID: 15313852

5

Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease.

Thalamas C, Rajman I, Kulisevsky J, Lledó A, Mackie AE, Blin O, Gillespie TA, Seger M, Rascol O. Thalamas C, et al. Among authors: rascol o. Clin Neuropharmacol. 2005 May-Jun;28(3):120-5. doi: 10.1097/01.wnf.0000168581.97083.9c. Clin Neuropharmacol. 2005. PMID: 15965310 Clinical Trial.

6

Contrasting changes in cortical activation induced by acute high-frequency stimulation within the globus pallidus in Parkinson's disease.

Payoux P, Remy P, Miloudi M, Houeto JL, Stadler C, Bejjani BP, Yelnik J, Samson Y, Rascol O, Agid Y, Damier P. Payoux P, et al. Among authors: rascol o. J Cereb Blood Flow Metab. 2009 Feb;29(2):235-43. doi: 10.1038/jcbfm.2008.107. Epub 2008 Sep 10. J Cereb Blood Flow Metab. 2009. PMID: 18781162 Clinical Trial.

7

Rotigotine transdermal delivery for the treatment of Parkinson's disease.

Rascol O, Perez-Lloret S. Rascol O, et al. Expert Opin Pharmacother. 2009 Mar;10(4):677-91. doi: 10.1517/14656560902746041. Expert Opin Pharmacother. 2009. PMID: 19239399 Review.

8

Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.

Rascol O, Azulay JP, Blin O, Bonnet AM, Brefel-Courbon C, Césaro P, Damier P, Debilly B, Durif F, Galitzky M, Grouin JM, Pennaforte S, Villafane G, Yaici S, Agid Y. Rascol O, et al. Mov Disord. 2010 Feb 15;25(3):368-76. doi: 10.1002/mds.22922. Mov Disord. 2010. PMID: 20063435 Clinical Trial.

9

Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Perez-Lloret S, Rascol O. Perez-Lloret S, et al. Among authors: rascol o. CNS Drugs. 2010 Nov;24(11):941-68. doi: 10.2165/11537810-000000000-00000. CNS Drugs. 2010. PMID: 20932066 Review.

10

Safety of rasagiline for the treatment of Parkinson's disease.

Perez-Lloret S, Rascol O. Perez-Lloret S, et al. Among authors: rascol o. Expert Opin Drug Saf. 2011 Jul;10(4):633-43. doi: 10.1517/14740338.2011.573784. Epub 2011 Apr 1. Expert Opin Drug Saf. 2011. PMID: 21453201 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

588 results

Search Page